Cancer Forums and News by PhD's


News | Forums

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
phase I
EntreMed Starts Phase II Clinical Trial of Panzem with Sutent for Kidney Cancer Patients
By HCat at 2007-03-13 03:58
 

    EntreMed, Inc has commenced a Phase 2 trial to evaluate the safety and efficacy of Panzem (2-methoxyestradiol; 2ME2) alone or in combination with Sutenttermterm (sunitinibterm) in patients with metastaticterm renal cell carcinomaterm. The University of Wisconsin, Paul P. Carbone Comprehensive Cancer Center will be the main center conducting the trial under the guidance of Dr. Glenn Liu. The trial will investigate Panzem’s potential to treat patients who are progressing on sunitinib.

     Panzem NCD uses Elan Drug Delivery's (Elan) NanoCrystal Colloidal Dispersion (NCD) technology, a technology that is being used in marketed pharmaceuticals. The NCD technology produces nanometer-sized particles, which are up to 500 times smaller than particles manufactured by conventional milling techniques. Panzem NCD works by blocking the VEGFterm receptor and by inhibiting HIF-1alpha. The theory behind Panzem’s anti-tumor effects is that renal cell cancers are frequently associated with VEGF and PDGF overexpression involving a HIF-1alpha mechanism. It is thought that patients who progress through the tyrosine kinase inhibitor response, such as those on the tyrosine kinase inhibitor sunitinib, have an increase in HIF-1alpha expression to compensate for the kinase inhibition in order to continue tumor growth. Dr. Liu has stated that this trial will test this hypothesis. Panzem NCD is also currently in Phase 2 clinical trials for brain, ovarian, carcinoid, and prostate cancers as well as in Phase 1 study in metastatic breast cancer.

read more | 6208 reads

Callisto Pharmaceuticals Starts Phase I Clinical Trial with L-Annamycin in Pediatric Relapsed and Refractory Acute Leukemia
By HCat at 2007-03-11 23:27
 

    Callisto Pharmaceuticals, Inc. opened a phase I clinical trial testing L-Annamycin in children and young adults on February 22nd and announced dosing on March 8th. The trial will test the drug in pediatric patiens with refractory or relapsed acute lymphocytic leukemiaterm (ALL) or acute myelogenous leukemia (AML). Patients with relapsed or refractory acute leukemia who have prior treatment with approved chemotherapeutics generally have a poor prognosis at this point in the disease and are in need of new agents.

read more | 2672 reads

New HDAC Inhibitor Coming to the US and to Begin Trials
By HCat at 2007-03-08 03:46
 

    Chidamide (CS055) has been licensed in a co-development deal between the San Diego-based company Huya Bioscience and the Chinese based company Shenzhen Chipscreen Biosciences. Shenzhen received approval for Chidamide in December from the SFDA for a phase I trial to begin in China. Huya plans to file Chidamide as an Investigational New Drug in the US as well as commence clinical trials here and in Europe.

    Chidamide is a histone deacetylase (HDAC) inhibitor from the benzamide class and is currently in phase I trials in China for Lung and Colon cancer patients. HDACs are thought to play a role in cancer through preventing histone acetylation which in turn prevents expression of DNA since the DNA cannot unwrap from the histones. This suppression of gene expression could promote cancerous growth if it silences tumor suppressor genes.

read more | 2088 reads

2007 Update of What is in the Oncology Pipeline at Glaxosmithkline
By HCat at 2007-03-07 07:05
 

    This is an update to the previous drug pipeline article covering 2006. Quite a few of the drugs from 2006 have been stopped with three new ones added.

559448, in license or other alliance relationship with a third party, is a thrombopoietin agonist indicated for use in thrombocytopaenia and in phase I

626616, in license or other alliance relationship with a third party, is a human kinase inhibitor indicated for use in chemoprotection and in phase I

read more | 5065 reads

Sunesis Pharmaceuticals SNS-314 Aurora Kinase Inhibitor Filed With the FDA
By HCat at 2007-03-04 00:06
 

    The third oncology program for Sunesis Pharmaceuticals to advance to the clinic, SNS-314 was filed as an Investigational New Drug (IND) with the FDA at the beginning of March.

    SNS-314 inhibits Aurora kinases A, B, and C. Stopping Aurora kinases halts cellular division at the mitotoic phase of the cell cycle. Preclinical studies of SNS-314 in mice tumor models have shown broad anti-tumor activity, and Sunesis plans to initially evaluate SNS-314 as a single agent in patients with advanced solid tumors in phase I clinical trials in the upcoming months. Sunesis also has SNS-595, a cell cycle inhibitor, in clinical phase II trials for lung cancer, ovarian cancer, and leukemiaterm.

read more | 2518 reads

What Is in the Pipeline at GlaxoSmithKline?
By HCat at 2007-02-26 12:09
 

743921(In license or alliance with a third party), a kinesin spindle protein (KSP) inhibitor, is an indicated therapy for cancer in phase I trials.

Elacridar, an oral bioenhancer, is an indicated therapy for cancer is in phase I trials.

Relacatib (In license or alliance with a third party), a cathepsin K inhibitor, is an indicated therapy for bone metastases (also osteoporosis & osteoarthritis) in phase I trials

read more | 2997 reads

Phase I Trial of Rigel' Aurora Kinase Inhibitor Begins
By HCat at 2007-02-15 02:04
 

    Announced February 13th on Rigel's site, the second of several phase I studies to evaluate the safety and initial efficacy of the candidate R763 in different types of cancers is starting. The trials will tests the inhibitor in solid tumors, hematological malignancies, and in combination with standard therapies.

    Merck Serono licensed development and commercialization rights to R763 and Rigel's Aurora kinase program in October 2005. Aurora kinases are a family of kinases (proteins that put phosphate groups on other proteins) that regulate mitosis (cellular division). It is thought that these kinases are deregulated in cancer, and culture cell studies have shown Aurora kinases have anti-tumor effects.

read more | 3426 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 03:23 PM.